Viewpoint: The DEWS Smartphone

For US optometrists, a new DEWS report can arguably be likened to a new iPhone

By: Jennifer Kirby, managing editor

Optometric Management July 16, 2025 Vol 60(6), Issue July/August 2025 Page(s): 4

Clinical Report: The DEWS Smartphone

Overview

The DEWS III report significantly expands on previous guidelines for dry eye disease (DED), providing a comprehensive framework for diagnosis and management. It emphasizes targeted therapies based on disease etiology, aiming to enhance clinical decision-making.

Background

The management of dry eye disease is critical for improving patient quality of life and ocular health. The DEWS III report serves as a pivotal resource for optometrists, offering updated definitions, risk factors, and management strategies. Its comprehensive nature reflects the evolving understanding of DED and the need for standardized approaches in clinical practice.

Data Highlights

No numerical data provided in the source material.

Key Findings

DEWS III is a 637-page report that revises the definition of dry eye disease.
It includes a prescribing algorithm to guide clinicians in selecting interventions based on disease etiology.
Diagnostic recommendations emphasize the OSDI-6 as the preferred screening tool.
Subclassification of DED is organized by tear film deficiencies, eyelid anomalies, and ocular surface abnormalities.
Management strategies are tailored to identified disease drivers, moving away from a one-size-fits-all approach.

Clinical Implications

Clinicians should integrate the DEWS III report with other reputable sources to enhance their understanding and management of dry eye disease. The report's emphasis on targeted therapies allows for more personalized patient care.

Conclusion

The DEWS III report represents a significant advancement in the understanding and management of dry eye disease, providing essential tools for clinicians to improve patient outcomes.

PentaVision

Optometric Management